Advice
In the absence of a submission from the holder of the marketing authorisation
trastuzumab (Herceptin) in combination with an aromatase inhibitor is not recommended for metastatic breast cancer.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice24KB (PDF)
Medicine details
- Medicine name:
- trastuzumab (Herceptin)
- SMC ID:
- 386/07
- Indication:
- metastatic breast cancer
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Superseded
- Date advice published
- 09 July 2007